Canagliflozin: a novel ‘glucuretic’ approach for the treatment of type 2 diabetes mellitus

Ravindra S. Beedimani1*, Bhuvaneshwari Kalmath2

1Department of Pharmacology, Kamineni Academy of Medical Sciences and Research Center, Hyderabad, Andhra Pradesh, India,
2Department of Oral Medicine and Radiology, Al-Badar Rural Dental College and Hospital, Gulbarga, Karnataka, India

Received: 25 February 2014
Accepted: 21 March 2014

*Correspondence to:
Dr. Ravindra S. Beedimani,
Email: ravisb123@gmail.com

© 2014 Beedimani RS et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Canagliflozin (Invokana, Janssen Pharmaceuticals) is the first in a new class of glucose-lowering drugs, an oral inhibitor of sodium glucose cotransporter 2 (SGLT2). SGLT2, the transporter is responsible for reabsorbing the majority of glucose filtered by the kidney. SGLT2 inhibitors are a new class of oral drugs indicated only for the treatment of type 2 diabetes mellitus in conjunction with exercise and a healthy diet. They inhibit glucose re-absorption in the proximal renal tubules providing an insulin independent mechanism to lower blood glucose. Their use in clinical studies is associated with improved glycemic control, weight loss, and a low risk of hypoglycemia. They have been studied alone and with other medications including sulfonylureas, sitagliptin, and insulin.

Keywords: Sodium-glucose cotransporter 2, Canagliflozin, Diabetes mellitus type 2

ABSTRACT

Canagliflozin is the first in a new class of glucose-lowering drugs, an oral inhibitor of sodium glucose cotransporter 2 (SGLT2). SGLT2, the transporter is responsible for reabsorbing the majority of glucose filtered by the kidney. SGLT2 inhibitors are a new class of oral drugs indicated only for the treatment of type 2 diabetes mellitus in conjunction with exercise and a healthy diet. They inhibit glucose re-absorption in the proximal renal tubules providing an insulin independent mechanism to lower blood glucose. Their use in clinical studies is associated with improved glycemic control, weight loss, and a low risk of hypoglycemia. They have been studied alone and with other medications including sulfonylureas, sitagliptin, and insulin.

Keywords: Sodium-glucose cotransporter 2, Canagliflozin, Diabetes mellitus type 2
Canagliflozin Cardiovascular Assessment Study (CANVAS), which the company is conducting to fulfill the 2008 FDA guidance regarding cardiovascular safety for investigational diabetes drugs. Final results of CANVAS, which enrolled a total of 4,330 individuals with cardiovascular disease (CVD) or at high risk for it, are not expected until 2015.

**DRUG DESCRIPTION**

Canagliflozin (INVOKANA, Janssen Pharmaceuticals) is supplied as film-coated tablets for oral administration, containing 100 mg and 300 mg of canagliflozin (anhydrous form).

**Indications**

Canagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

**Dosage**

The recommended starting dose of canagliflozin is 100 mg once daily, taken before the first meal of the day. In those patients that require additional glycemic control, the dose can be increased to 300 mg once daily provided they have good renal function. No dose adjustment is needed in patients with mild renal impairment (GFR of 60 mL/min/1.73 m²).

**PHARMACODYNAMICS: MECHANISM OF ACTION**

Sodium-dependent glucose cotransporters (or sodium-glucose linked transporter, SGLT) are a family of glucose transporter found in the enterocytes of the small intestine (SGLT1) and the proximal convoluted tubule of the nephron (SGLT2). SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion.

**Metabolism**

O-glucuronidation is the major metabolic elimination pathway, mainly by UGT1A9 and UGT2B4 to 2 inactive O-glucuronide metabolites and CYP3A4-mediated (oxidative) metabolism is minimal (~7%).

**Elimination**

Half-life: 10.6 hr (100 mg dose); 13.1 hr (300 mg dose).

Total body clearance: 192 mL/min.

**Excretion**

Feces: 41.5% (canagliflozin), 7% (hydroxylated metabolite), 3.2% (O-glucuronide metabolite).

Urine: 33% excreted in urine, mainly as O-glucuronide metabolites (30.5%); <1% excreted unchanged.

**Clinical results**

In clinical trials, canagliflozin improved hemoglobin A1c (HbA1c) levels and fasting and postprandial blood glucose levels and was associated with weight loss in patients with type 2 diabetes. The safety and efficacy of the drug were tested in nine clinical trials involving more than 10,000 patients with type 2 diabetes. Canagliflozin monotherapy helped more patients achieve the American Diabetes Association (ADA)-recommended HbA1c goal of <7.0% over 26 weeks vs. placebo. Canagliflozin 300 mg helped more patients achieve the ADA-recommended HbA1c goal of <7.0% than sitagliptin 100 mg over 52 weeks. In patients tolerating the starting dose of canagliflozin 100 mg once daily who have an eGFR of ≥60 mL/min/1.73 m² and require additional glycemic control, the dose can be increased to 300 mg once daily. Canagliflozin 300 mg helped more patients achieve the ADA-recommended HbA1c goal of <7.0% than glimepiride over 52 weeks. The dose of canagliflozin is limited to 100 mg once daily in patients with moderate renal impairment with an eGFR of 45 to <60 mL/min/1.73 m². It should not be initiated in patients with eGFR <45 mL/min/1.73 m². At 26 weeks, canagliflozin monotherapy provided statistically significant weight reductions vs. placebo, though it is indicated for weight loss. Furthermore, at 26 weeks, canagliflozin monotherapy provided statistically significant systolic blood pressure reductions versus placebo.

**Adverse reactions**

The most commonly reported adverse reactions (≥5%) were female genital mycotic infection, urinary tract infection, and increased urination. Less commonly noted adverse effects (≤5% but more than 1.5%) includes male genital...
mycotic infection, vulvovaginal pruritus, thirst, constipation and nausea. Patients may also experience dizziness or fainting, especially in the first 3 months of therapy, because canagliflozin is associated with a diuretic effect, which can reduce intravascular volume, leading to orthostatic or postural hypotension.

**Drug interactions**

Co-administration of canagliflozin with rifampin, a nonselective inducer of several UDP-glucuronyl transferase (UGT) enzymes, including UGT1A9, UGT2B4, decreased canagliflozin area under the curve by 51%. This decrease in exposure to canagliflozin may decrease efficacy. If an inducer of these UGTs (e.g., rifampin, phenytoin, and phenobarbital) must be co-administered with canagliflozin, consider increasing the dose to 300 mg once daily if patients are currently tolerating canagliflozin 100 mg once daily, have an eGFR >60 mL/min/1.73 m², and require additional glycemic control.

**Warning and precautions**

Orthostatic hypotension has been noted with canagliflozin and thus patients’ volume status should be assessed and corrected, as necessary, before and during treatment. The use of canagliflozin in combination with insulin therapy or an insulin secretagogue (e.g., sulfonylureas) was associated with a higher incidence of hypoglycemia and may require a lower dose of insulin or an insulin secretagogue to reduce the risk of hypoglycemia. Dose-related increase in LDL-C is noted with canagliflozin in four 26-week placebo-controlled trials.²

**Contraindication**

Other than history of hypersensitivity reactions to canagliflozin, it should not be initiated in patients with severe renal function impairment (eGFR of less than 30 mL/min/1.73 m²), with end-stage renal disease, or receiving dialysis. Canagliflozin is not expected to be effective in these patient populations.

**Use in special populations**

There are no adequate and well-controlled studies of canagliflozin in pregnant women and nursing mothers. During pregnancy, consider appropriate alternative therapies, especially during the second and third trimesters. Patients ≥75 years of age had a higher incidence of adverse reactions related to reduced intravascular volume with canagliflozin (such as hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration), particularly with the 300-mg daily dose, compared to younger patients; more prominent increase in the incidence was seen in patients who were ≥75 years of age.

**CONCLUSIONS**

The newly licensed novel glucose-lowering drug canagliflozin (Invokana, Janssen Pharmaceuticals) is a welcome addition to the armamentarium of treatment for type 2 diabetes mellitus. Canagliflozin, SGLT2 inhibitor, is a new class of oral drugs indicated only for the treatment of type 2 diabetes mellitus in conjunction with exercise and a healthy diet. Canagliflozin offer a novel insulin-independent approach for the control of hyperglycemia without incurring hypoglycemia. Their efficacy is not affected by the extent of insulin resistance or beta-cell dysfunction and, therefore, in principle, can be used at any stage in the natural history of type 2 diabetes mellitus. Initial studies suggest they can be used as monotherapy or in combination with sulfonylureas, sitagliptin and insulin. Treatment is associated with a mean weight loss and a small reduction in blood pressure, which also may appear beneficial to patients with coexisting CVD, but further clinical trial results regarding long-term cardiovascular outcomes are needed to confirm the same.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

**REFERENCES**

1. Nisly SA, Kolanczyk DM, Walton AM. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. Am J Health Syst Pharm. 2013;70(4):311-9.
2. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013;9(6):763-75.
3. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-82.
4. Polidori D, Sha S, Mudaliar S, Ciarelli TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154-61.
5. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-15.
6. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28(7):1167-71.

**Cite this article as:** Beedimani RS, Kalmath B. Canagliflozin: a novel ‘glucuretic’ approach for the treatment of type 2 diabetes mellitus. Int J Basic Clin Pharmacol 2014;3:578-80.